All In Biotech

Drug Trial Radar · NCT04576949

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 810 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

810

Actual

Start

Oct 13, 2020

Primary completion

Dec 23, 2021

Study completion Dec 23, 2021

Sponsor

Lead sponsor
Achieve Life SciencesIndustry
Sponsor type
Industry
First posted
Oct 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.

Conditions

  • Smoking Cessation

Interventions

  • CytisiniclineDrug

    film-coated oral tablets containing 3 mg cytisinicline

  • PlaceboDrug

    film-coated oral tablets containing matched placebo

  • Behavioral supportBehavioral

    Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6Time frame: Weeks 3 to 6
  2. Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12Time frame: Weeks 9 to 12

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research, LLC.

    Mobile, Alabama

  • Arizona State University

    Phoenix, Arizona

  • Alliance for Multispecialty Research, LLC

    Coral Gables, Florida

  • Clinical Research Atlanta

    Atlanta, Georgia

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana

  • Alliance for Multispecialty Research, LLC

    Wichita, Kansas

  • AMR Lexington

    Lexington, Kentucky

  • Alliance for Multispecialty Research, LLC

    New Orleans, Louisiana

  • Massachusetts General Hospital - Clinical Genetic Research Facility

    Boston, Massachusetts

  • Alliance for Multispecialty Research, LLC

    Kansas City, Missouri

  • Alliance for Multispecialty Research, LLC

    Las Vegas, Nevada

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • M3 Wake Research, Inc.

    Raleigh, North Carolina

  • Coastal Carolina Research Center, Inc.

    Mt. Pleasant, South Carolina

  • Alliance for Multispecialty Research, LLC.

    Knoxville, Tennessee

  • FutureSearch Trials of Dallas, LP

    Dallas, Texas

  • Alliance for Multispecialty Research, LLC

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.